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Abstract: The ABC (ATP Binding Cassette) transporter protein superfamily comprises a 
large number of ubiquitous and functionally versatile proteins conserved from archaea to 
humans. ABC transporters have a key role in many human diseases and also in the 
development of multidrug resistance in cancer and in parasites. Although a dramatic progress 
has been achieved in ABC protein studies in the last decades, we are still far from a detailed 
understanding of their molecular functions. Several aspects of pharmacological ABC 
transporter targeting also remain unclear. Here we summarize the conformational and 
protonation changes of ABC transporters and the potential use of this information in 
pharmacological design. Network related methods, which recently became useful tools to 
describe protein structure and dynamics, have not been applied to study allosteric coupling in 
ABC proteins as yet. A detailed description of the strengths and limitations of these methods 
is given, and their potential use in describing ABC transporter dynamics is outlined. Finally, 
we highlight possible future aspects of pharmacological utilization of network methods and 
outline the future trends of this exciting field. 
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1. INTRODUCTION 
 
ABC transporters (ATP Binding Cassette transporters) have been in the forefront of 
pharmacological studies for many years, since several severe human illnesses, such as cystic 
fibrosis, Dubin-Johnson syndrome or adrenoleukodystrophy have been linked to mutations 
leading to the dysfunction of certain ABC transporters [1–4]. In addition, multidrug-resistance 
of cancer cells has been shown to be mediated by ABC transporters responsible for the 
extrusion of xenobiotics from cells [5]. Thus, ABC transporters are popular target candidates 
for the design of drugs to either rescue or attenuate transporter activity. 
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 ABC exporters harvest the energy of ATP binding or hydrolysis to actively transport their 
substrates into the extracellular medium [6]. Mutagenic experiments and structures 
determined by X-ray crystallography suggest that substrate and ATP binding occur in 
spatially distant regions of the protein [7–12]. The nucleotide binding domains (NBDs) act in 
a pair, and bind two ATP molecules cooperatively on their common interface [13], while in 
known cases drug binding and transport occur in the transmembrane domains (TMDs) [7–
9,12]. ATP binding and hydrolysis are necessary for drug transport [6], and the binding and 
transport of drugs, in turn, stimulate transporter ATPase activity [9,14,15], suggesting the 
existence of active communication between the drug binding site(s) and the NBDs.  
 
Available X-ray structures of exporter-type full transporters (Sav1866 [10], MsbA [11], 
mMDR1A [12], TM287/288 [unpublished, PDB IDs: 3QF4, 3QF5], hABCB10 [unpublished, 
PDB IDs: 2YL4, 4AA3]) and the variety of their transported substrates suggest that ABC 
transporters are very flexible molecules that can achieve various conformations in the 
membrane during the transport cycle. Several mechanistic models have been developed to 
describe the details and the order of the putative events in the transport cycle [6,13,16–19]. 
However, a consensus mechanism of action has not been obtained that could be applicable to 
these ABC transporters. To understand the mechanism how drugs stimulate the ATPase 
activity, to elucidate the action of inhibitors, and the mode of transport of large substrates, the 
consideration of the dynamic behavior of ABC transporters is necessary. 
 
In the last decades network related methods emerged as powerful tools to determine key 
properties of protein structure and dynamics. In the representations of protein structure 
networks (also called protein contact networks, or residue interaction networks) amino acid 
side chains represent the nodes of the network. The edges of protein structure networks are 
derived from the distance between the side chains [20–27]. Other network-related methods, 
such as elastic network models, the statistical mechanics approaches of Gaussian network 
models and normal mode analysis, proved to be extremely useful to explore protein dynamics 
[28–37].  
 
In this review we describe the strengths and limitations of these network representations in 
detail, and will show their usefulness in the description of conformational and protonation 
changes. First we summarize key aspects of conformational and protonation changes of ABC 
transporters and their importance in pharmacological design. In Section 3 several potent, 
network-related tools to assess conformational and protonation changes are described. We 
highlight several potential applications of the dynamic network description of ABC 
transporters in Section 4 and conclude the review by listing the most important trends of the 
field.  
 
2. ROLE OF CONFORMATIONAL CHANGES AND PROTONATION STATES IN 
THE FUNCTION OF ABC TRANSPORTERS 
 
2.A. Conformational transitions of ABC transporters. The structural elucidation of 
ABC transporters has not started until recently because the crystallization of large membrane 
proteins is tedious and challenging. Still, several atomic resolution structures of both bacterial 
and eukaryotic full ABC transporters have been solved (BtuCD [38], HI1470/71 [39], ModBC 
[40], MalFGK2 [41], MetNI [42], Sav1866 [10], MsbA [11], mMDR1A [12], PDB IDs 
without reference: hABCB10 [2YL4], TM287/288  
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[3QF4]). While all of them share a similar domain composition 
having two nucleotide binding (NBD) and two transmembrane 
domains (TMD) per active transporter, the number of domains on 
one polypeptide chain and the topological organization of trans-
membrane helices vary. 
 Among the ABC proteins with available crystal structures, bac-
terial ABC importers feature all four domains on separate chains 
and contain either 10+10 transmembrane helices forming a densely 
packed structure (structures of BtuCD, HI1470/71) or 6+6 trans-
membrane helices (structures of ModBC, MetNI, MalFGK2). Bac-
terial and eukaryotic ABC exporters with available structure usually 
contain a TMD and an NBD on one polypeptide chain (structures of 
Sav1866, MsbA, TM287/288, hABCB10) and function as homo- or 
heterodimers, or have all four domains on a single chain 
(mMDR1A). Exporters also feature 6+6 transmembrane helices, 
although organized in a different topology than importers. In spite 
of their similar domain composition, the different membrane to-
pologies suggest that the mechanism of action may not be similar in 
all ABC transporters [43]. 
 Conformations of ABC exporters seen in currently available X-
ray structures can roughly be classified into three groups, based on 
the separation between the NBDs and the orientation of the trans-
membrane domain (Fig. 1). In the presence of nucleotides, the 
transporters form a so-called “bottom-closed” conformation, where 
the two NBDs associate to form a tightly bound dimer-like struc-
ture, and the transmembrane domains are in an outward-facing 
conformation (PDB IDs: 2HYD, 3B60). These structures also re-
veal that ATP binding occurs at two pseudo-symmetric sites on the 
interface of the associated NBDs, where the nucleotides are sand-
wiched between the two protein domains. In crystals without nu-
cleotides (the apo state), the transmembrane domains are in the 
inward-facing conformation, and the nucleotide binding domains do 
not associate. The extent of separation between the NBDs in the 
apo structures show large variations ranging from 30 to 70 Å, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Conformations of ABC exporters. Representatives of the three groups of currently available ABC exporter X-ray structures are shown. (A) The 
nucleotide bound (holo) state is represented by the Sav1866 bacterial exporter (PDB ID: 2HYD), where the nucleotide binding domains are tightly associated 
and the transmembrane domain is in the outward-facing conformation. (B) A “bottom closed” apo conformation is structurally intermediate between the (A) 
and (C) states. The NBDs are separated but in contact with each other, and the substrate binding cavity within the transmembrane region is open toward the 
interior of the cell. This conformation can be observed for the MsbA transporter (PDB ID: 3B5X). (C) In the “bottom open” apo conformation, the NBDs are 
widely separated not contacting each other and the transmembrane domain is clearly in the inward-facing state. This is represented by the mouse MDR1A 
structure (PDB ID: 3G5U). The red arrows indicate the orientation of the N-terminal “elbow” helices that are parallel to the membrane surface as a common 
frame of reference. The membrane is shown in grey. (The color version of the figure is available in the electronic copy of the article). 
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which further divides the inward-facing conformations into a group 
where the NBDs are in contact with each other (PDB IDs: 3B5X, 
2YL4), and to another group where the NBDs are completely sepa-
rated (PDB IDs: 3B5W, 3G5U). It is remarkable that a single trans-
porter can display conformations belonging to either group, as 
demonstrated by the three independent structures of the MsbA ex-
porter (PDB IDs: 3B60, 3B5X, 3B5W). These three conformational 
groups are often viewed as representing different states along the 
transport cycle. These structures also fulfill the first two of the three 
basic requirements of the simple membrane pump model proposed 
by Jardetzky [44], by containing a cavity that can open toward ei-
ther side of the membrane, and is large enough to accept substrates. 
The model requires that substrate binding sites reside in the cavity, 
which is also suggested by mutagenesis studies [7,8,45] and by the 
mouse MDR1A X-ray structure with a bound inhibitor [12]. The 
substrate binding cavity should also have lower affinity in the out-
ward-facing state than in the inward-facing state to facilitate the 
dissociation of the transported substrate. It has been suggested 
based on structural and drug binding data that rotation of trans-
membrane helices during the conformational switch to the outward-
facing state causes crucial drug binding residues to become buried 
within the domain or even facing the lipid bilayer, which enables 
the dissociation of the substrate [46]. 
 Thus, based on the structures, it is relatively easy to deduce a 
simple mechanistic model for the transporters. According to this 
simple model, the switch from the inward-facing to the outward-
facing state of the transmembrane domain occurs with the associa-
tion of NBDs upon nucleotide binding, the substrate binding sites 
residing in the transmembrane domains. The coupling between the 
cytoplasmic and the transmembrane regions is provided by short 
helix segments connecting the cytoplasmic ends of the transmem-
brane helices. These regions of the transmembrane domains are 
referred to as coupling helices because they are tightly associated 
with the NBDs in all known structures and are proposed to form a 
junction that is responsible for allosteric communication between 
the TMDs and the NBDs [10]. Even such a simple mechanistic 
model shows that ABC exporters can undergo large conformational 
changes during the transport cycle. 
 It should be emphasized that X-ray structures only represent 
snapshots of the transporter that has been stabilized under the crys-
tallization conditions, and should therefore be considered with cau-
tion and scrutinized for consistency with other biochemical data 
[43]. Several other methods in tandem with structure determination 
have been used to develop more elaborate mechanisms of ABC 
exporter function. Early models were based on ATPase inhibition 
studies by vanadate or beryllium-fluoride, which can trap the sys-
tem in the transition state of hydrolysis [19]. Vanadate trapping 
experiments in human P-glycoprotein showed that hydrolysis at a 
single site is enough to drive the transport cycle and suggested an 
alternating ATP hydrolysis model [13,47]. However, studies on 
isolated NBD dimers were unable to trap an asymmetric ATP/ADP 
bound state that would be predicted by the alternating sites model 
[17]. In addition, it was shown that NBD dimer formation is de-
pendent on ATP binding [17]. In view of these findings, and also 
supported by X-ray structures of NBD dimers which contained 
nucleotides in both binding sites, the processive clamp model (or 
switch model) was proposed [6,17]. This model, in contrast to the 
alternating sites model, postulates that hydrolysis of both ATPs is 
required for the dissociation of the NBDs, which is in turn neces-
sary for the commencement of the transport cycle. 
 The presence of TMDs also seems to affect NBD association 
and ATP hydrolysis, as substrate binding stimulates ATPase activ-
ity only in transporters having both NBD and TMD domains 
[17,48]. Moreover, several heterodimeric and single-chain full 
transporters contain a degenerate ATP-binding site, rendering the 
ATPase activity of that site ineffective [49-51]. Thus, it is not clear 
how the switch model should be interpreted in these cases. There is 
also a discrepancy between mechanistic models regarding whether 
a large and complete separation between the NBDs occurs during 
transport. While chemical cross-linking studies of Loo and Clarke 
[52] showed that human MDR1 is able to function while the cyto-
plasmatic parts of the transmembrane domains are cross-linked, the 
solved apo structures of the MsbA and mouse MDR1A transporters 
display a large separation between the NBDs. As of yet, no consen-
sus model of ABC exporter mechanism has been established that is 
able to reconcile all experimental findings and structures. 
 Since conformational transitions are hard to probe experimen-
tally, molecular simulation methods have also been used to eluci-
date conformational changes at important points of the transport 
cycle. As ATP binding has been shown to promote the association 
of NBDs, it has been argued that ATP binding rather than hydroly-
sis can be the driving force behind the transport cycle [53]. Since 
the ATP-stabilized NBD dimer is very stable in hydrolysis-deficient 
mutants [17], the hydrolysis of ATP in a fully functional transporter 
is expected to trigger later events of the transport cycle, such as 
resetting the original high-affinity drug binding conformation.  
 Changes in conformation and dynamics occurring directly after 
ATP hydrolysis are often studied by molecular dynamics simula-
tion, by the in silico replacement of ATP with ADP or ADP+Pi. 
These simulations have shown an opening of the NBD interface at 
the hydrolysis site due to the loss of interactions with the gamma 
phosphate [19,54,55]. In addition, the so-called helical subdomain 
of the NBD, nearest to the hydrolyzing site, undergoes an outward 
rotation similar to the one observed in X-ray structures of mono-
meric NBDs [19,54-57]. The effect of ATP hydrolysis has also 
been studied in the full length Sav1866 bacterial exporter either by 
ADP or ADP+Pi replacement [58-60] or by nucleotide removal 
[58,60-62]. It was found that the outward-facing cavity of the 
transmembrane region can undergo spontaneous closure upon hy-
drolysis [59-61], and ATPase site opening was also observed in 
these studies [58,59,62], although not to the same extent as in iso-
lated NBD dimers. Some studies have aimed to describe a putative 
sequence of events in the full transporter, occurring after ATP hy-
drolysis, and these simulation results suggest that destabilization of 
the helix bundle, formed by the cytoplasmic extensions of the 
transmembrane helices, might be one of the first steps in the switch 
toward the inward-facing conformation [59,63]. The disruption of 
the bundle opens the inner cavity toward the cytoplasm, and the 
rearrangement of the transmembrane helices completes the confor-
mation change [63]. While the effect of ATP hydrolysis on the 
NBDs and TMDs has been extensively studied, the mechanism of 
ATPase activity stimulation by drug binding, where intramolecular 
signaling is expected to occur in the reverse direction from the 
TMDs towards the NBDs, still remains elusive and its structural 
basis remains to be understood. 
 ABC transporters are integral membrane proteins, still, in many 
cases the effects of different lipid environments (e.g. ER versus 
PM, mammalian versus insect membrane) on the conformation, 
dynamics and function is neglected. In the case of ABCG proteins 
the protein function is strongly dependent on the types of sterols 
specific to the species. The yeast Pdr12p transporter functions in the 
presence of ergosterol but not in cholesterol [64]. In contrast, the 
human ABCG2 is active in the presence of cholesterol, which can-
not be fully substituted by ergosterol or sitosterol [65]. Nonetheless 
the latter sterols also form membrane rafts. Interestingly, the Gly 
and Thr variants of the Arg482 amino acid located presumably in 
the interface with the inner leaflet of the lipid bilayer have different 
cholesterol sensitivity that the wild-type ABCG2. All these data 
suggest that the interaction of ABCG proteins with sterols is highly 
specific and the sterols do not simply provide an environment for 
the conformational changes. These lipids may be structural parts of 
the proteins and serve as cofactors. Cholesterol dependent function 
of MDR1 has also been reported [66], although this could not be 
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observed with either MDR1 or MRP1 under the same conditions 
applied for ABCG2 [65]. 
 The role of the above described conformational changes in 
ABC proteins is to move substrates through a membrane bilayer. 
Although one large binding pocket exists in currently accepted 
models, functionally at least two different binding sites are pre-
dicted that may be either at different locations of the biding pocket 
or may physically overlap [14]. These sites exhibit preferential 
binding of different substrates, e.g. in MDR1 one site binds vera-
pamil, while the other Hoechst 33342. It also seems evident that the 
induced fit mechanism can explain the wide substrate specificity of 
MDR transporters. Binding of different substrates has been demon-
strated to result in different conformations of the transmembrane 
helices based on MDR1 cross-linking experiments [67]. However, 
the conformational selection theory, which is an alternative mecha-
nism for molecular recognition, came to the focus of research again 
in the last decade [68-72]. According to conformational selection 
theory, all possible conformations of the protein are realized in the 
absence of substrates, even those conformations that are capable to 
bind substrates. The substrate selects the favored conformation to 
bind to.  
 In the case of ABC transporters this mechanism would not sim-
ply be an alternative of induced fit for recognition of an extremely 
wide set of drugs, but could also provide explanation for the follow-
ing phenomena. Multidrug transporters express high basal ATPase 
activity when the ATP consumption is not coupled to the presence 
and movement of any drug [73]. Although basal activity is being 
proposed as a requirement for low substrate selectivity [74], we are 
far from understanding this phenomenon. According to conforma-
tional selection theory, drug binding conformations that are also 
responsible for ATP cleavage in basal activity are also realized in 
the absence of any drugs. The presence of a drug would shift the 
conformational ensemble towards the binding competent conforma-
tion exhibiting the increased, drug-stimulated ATPase activity. 
Unexpectedly, some transported substrates do not increase ATPase 
activity in the case of several transporters such as yeast Pdr5, Cdr1, 
and human ABCG2 [49,75,76]. This behavior can be explained by 
the ATPase competent conformational ensemble being narrowed by 
the presence of the substrate. The conformation selection model can 
also provide an explanation of altered substrate specificities when a 
mutation is located clearly outside a substrate binding region or in 
the nucleotide biding domains [49,77,78]. Interestingly, the type of 
the nucleotide has also been reported to alter substrate specificity in 
Pdr5 [49,79]. In these cases, either the mutation or the modified 
nucleotide alters the dynamics of the NBD, which is strongly cou-
pled to the transmembrane domains (see CFTR as a well-studied 
example in Section 2.C), and thus the conformational ensemble of 
the transporter is changed to favor conformations binding different 
drugs than the wild type transporter. Interestingly and importantly, 
thermodynamic analysis indicated that etoposid and colchicine are 
transported by the G185V variant of MDR1 more efficiently com-
pared to the wild type, since this mutant requires fewer bond rear-
rangements to reach the transition state [80]. This mutation may 
shift the structural ensemble to favor conformations that are closer 
to the transition state of etoposid and colchicine transport. The ki-
netic substrate selection model, in many ways similar to conforma-
tional selection, has been described for ABC transporters [9]. 
 A mechanism similar to conformation selection may be respon-
sible for channel gating of CFTR, where the role of the substrate in 
changing the structural ensemble is substituted by PKA phosphory-
lation of the intrinsically disordered R domain of this channel. It 
has been implied that the phosphorylation of numerous PKA con-
sensus sites leads to altered ordered/disordered states of the R do-
main, resulting in altered interactions of this regulatory domain 
with NBD1 [81]. However, if the unphosphorylated R domain in-
tercalates between NBDs, and inhibits transporter function by coun-
teracting NBD dimer formation, then alternative activation mecha-
nisms provided e.g. by dATP [82] or vitamin C [83] cannot be ex-
plained. Conceivably, the R domain acts as a constraint between the 
two halves of the channel, and its phosphorylation results in altera-
tions in the dynamics of CFTR, shifting the conformational ensem-
ble toward a state, which is more likely to open [84]. dATP and 
vitamin C molecules may act similarly on the unphosphorylated 
protein by altering the conformational space available. 
 In order to rationally develop successful pharmacological appli-
cations it would be important to learn more about the dynamics of 
ABC transporters. However, the experimental study of the dynam-
ics of ABC transporters is extremely challenging because these are 
large membrane proteins difficult to express at sufficient quantities 
for biochemical studies, and are also sensitive to purification and 
reconstitution. The methods that can be applied to full length trans-
porters, such as fluorescent quenching and accessibility measure-
ments, have their limitation and yield no directional and quantita-
tive information on protein movements. Although chemical cross-
linking experiments provide distance information, they possess a 
different type of limitation. Since cross-linking is an irreversible 
process, conformations that are present only with a very low prob-
ability can also be detected. Most likely because of this property of 
cross-linking, a single, most favorable structure determined by crys-
tallization cannot be expected to satisfy all of the measured dis-
tances (for a review see [43]). While a distance distribution can be 
determined between two spin-labeled amino acids using EPR spec-
troscopy, it might not represent one single conformation, since the 
distance of two residues can be the same in different conformations. 
Directional information on the movements is also lacking in EPR 
experiments. Current computational tools and resources also pose 
limitations in assessing the dynamics of ABC transporters. For 
example, molecular dynamics simulations have limited time scale 
because of the large size of the system (a large protein and lipids to 
form a bilayer). However, combining of data from different meth-
ods, such as NMR spectroscopy of isolated NBDs, cross-linking 
experiments of the full length proteins and simulation with simpli-
fied models may provide solid and sufficient information on dy-
namics for pharmacological applications. 
2.B. Protonation States of ABC Transporters 
 There is very little information about the protonation states of 
ABC transporters. Their function in most cases does not seem to 
involve transport of protons, and ABC protein function is not al-
tered by small changes in pH. Interestingly, LmrA, a Lactococcus 
lactis homolog of human MDR1, has been shown to be a symporter 
of proton and ethidium [85]. Although human MDR1 has also been 
suggested to function as a proton pump [86], measurable proton 
transport activity could not be detected [87]. 
 Since it is not trivial to determine the hydrophobicity of amino 
acid side chains, it is also difficult to learn about their partitioning 
and pKa in a membrane environment [88,89]. Recent computational 
works have explored the protonation states of arginine in a mem-
brane bilayer and found that lipid composition affects the stability 
of different protonation states [90]. However, the situation is highly 
complex in a membrane protein, since in many cases the side chain 
of an amino acid is not exposed to the hydrophobic core of the bi-
layer. The side chain may point to the interface region or toward 
another transmembrane helix of the protein and it is difficult to 
judge if the properties of the environment resemble a hydrophilic or 
a hydrophobic surrounding, promoting protonation or deprotona-
tion. Arginines located in transmembrane helix 6 have been shown 
to line the channel pore in CFTR [91,92]. It is proposed that rota-
tional movements make the positively charged arginines inaccessi-
ble for chloride ions [93]. This rotation, during which the protona-
tion state of the arginines may or may not change, provides a possi-
ble mechanism for fast opening and closing of the channel through 
two conformational states with relatively low energy barriers. Here 
we refer to the fast open/close burst, not to the long closed state of 
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the channel upon ATP hydrolysis at the second NBD [94]. Similar 
rotational movements may be responsible for disrupting and take 
away the binding sites in multidrug transporters to allow the sub-
strate dissociate from the protein. 
 The protonation states of histidines in ABC multidrug trans-
porters have turned out to be structurally very important. Recent 
computational results indicate that the correct protonation state of 
histidines (the catalytic His583 and His1228, as well as His149 
from intracellular loop 1, for the position of the catalytic histidines, 
see Fig. 2) and the presence of magnesium ions during simulations 
with the inward-facing, “bottom open” structure of mouse MDR1A 
are essential for running stable stimulations (M. L. O’Mara, per-
sonal communication). These minor but crucial environmental 
changes propose a nucleotide free structure, in which the trans-
membrane domains are separated at the bottom as in the crystal 
structure, but the nucleotide binding domains get close to each other 
and form contacts similar to the open state of MalK [95]. In addi-
tion to histidines, there are several other residues whose protonation 
states might be important during ATP hydrolysis, including a glu-
tamic acid that is proposed to form a “catalytic dyad” together with 
a histidine [96] (Fig. 2). 
 In addition to the protonation state of the membrane protein, the 
protonation state of transported substrate is also important. First, 
protonation can influence the membrane permeability of drugs, as 
molecules with charges cannot easily penetrate the bilayer. Second, 
the protonation state defines whether or not a molecule can accept 
or donate hydrogen bonds that can be crucial in drug recognition by 
ABC transporters. Omote and Al-Shawi have studied the effect of 
protonation state on the membrane permeation of different MDR1 
substrates [97]. For example, the deprotonated form of verapamil 
could enter the hydrophobic core of the bilayer, while the proto-
nated form, similarly to other modeled substrates, maintained its 
interaction with the head groups of lipids and with water in the 
interfacial region. Thus the protonation state can determine the 
most probable position of a certain molecule in the bilayer and so 
may influence whether that molecule has access to the main drug 
binding chamber. Since the MDR1 multidrug transporter favors 
positively charged molecules as substrates [98,99], the entry point 
of the substrate in the protein may be defined by negatively charged 
amino acids. The lateral opening between transmembrane helices 4 
and 6 could potentially serve as an entry point for substrates in the 
“bottom open” structure of mouse MDR1A, and the equivalent 
region in the human MDR1 contains negatively charged residues 
(e.g. E353 and D997, see Fig. 2) that may act as selection filters. 
This presumption is reinforced by the fact that these amino acids 
are homologous to the E314 of the above mentioned LmrA, in 
which glutamic acid plays a role in proton transport [100]. The 
binding chamber contains not only hydrophobic but also charged 
residues and hydrogen bond acceptors that may form a H-bonding 
ladder, a pathway for the protonated and positively charged drugs 
leading toward the extracellular region of the transporter. 
2.C. Pharmacological Applications of ABC Transporter Dy-
namics 
 ABC transporters are important drug targets in many human 
diseases. In several pathological situations the functional expression 
of ABC proteins needs to be corrected. The most prominent exam-
ple is cystic fibrosis, where the mutant forms of CFTR (ABCC7) 
need to be rescued from a misfolded state [101]. Other diseases in 
which some of the mutations likely cause abnormal protein folding 
and decreased function include Stargardt’s disease and retinitis 
pigmentosa (ABCA4; [102,103]), pseudoxanthoma elasticum 
(ABCC6; [104]). In the case of the treatment of various diseases the 
function of multidrug transporter ABC proteins should to be inhib-
ited (for recent reviews see [105] and [106]). For example, blocking 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Protonation states of ABC transporters. The protonation state of residues is especially important near the nucleotide binding region, where ATP 
hydrolysis occurs, and near the putative drug binding regions. The homology models of human MDR1 (A) in the outward-facing conformation based on the 
Sav1866 structure [238] and (B) in the inward-facing conformation based on the mouse MDR1A structure are shown as an illustration. Residues whose proto-
nation state could be important in drug binding and selectivity are indicated in red (Glu353, Asp997, His61). (C) The ATP binding site is enlarged and canoni-
cal residues are highlighted in the Sav1866 AMP-PNP bound structure (PDB ID: 2ONJ) that are important in ATP binding and hydrolysis. While the Tyr349 
residue stabilizes the adenosine moiety, several residues, such as Gln422, Glu503 or Lys380 take part in coordinating either the phosphate groups or the mag-
nesium ion of bound MgATP. The His534 residue, which is expected to be doubly protonated [239] is thought to form a “catalytic dyad” with Glu503 [96] and 
coordinate the water molecule that performs the nucleophilic attack on the phosphate group. (The color version of the figure is available in the electronic copy 
of the article). 
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the function of human MDR proteins in the gut would enhance the 
absorption of orally administered drugs, in the blood-brain barrier 
would increase the concentration of drugs in the brain that target the 
central nervous system (e.g. antidepressants), and in cancer cells 
would allow reaching the effective cellular concentration of anti-
cancer agents. To develop a successful pharmacological approach 
that modulates the function of ABC transporters, targeting a static 
structure is unlikely to be sufficient. Without attempting to be com-
prehensive, we demonstrate how the knowledge of ABC protein 
dynamics can be important for pharmacological applications. As an 
example we employ CFTR, whose dynamics is the most well stud-
ied among human ABC transporters. 
 Although many folding mutants of CFTR are known, the dele-
tion of Phe at position 508 (F508) is present in most of the cystic 
fibrosis patients, thus this mutation is widely studied [101]. Earlier 
studies based on the Trp fluorescence of isolated polypeptides 
showed that F508 diverts the CFTR NBD1 domain, where this 
amino acid is localized, to an off-folding pathway [107,108]. Fold-
ing simulations employing a simplified protein model also demon-
strated that this deletion alters the folding kinetics of this domain 
[109]. Although the latter study pointed to specific conformations 
and specific amino acids that could be targeted to correct the fold-
ing pathway, because of the complexity of this process and our 
limited knowledge on protein folding, drug development and treat-
ment could not be designed based on this observation. It has also 
been shown that the deleterious effect in the NBD influences do-
main-domain interactions and also propagates to the transmembrane 
domains [110,111], since the F508 is a crucial residue at the NBD 
and TMD interaction interface [112]. 
 The F508 mutation was expected to cause dramatic misfolding 
of the NBD1, while the X-ray structures of the wild type and mu-
tant isolated domains are highly similar [113]. It is important to 
note that most of these structures contain mutations that increase 
solubility or rescue the full length F508 protein. Moreover, the 
crystallization conditions (e.g. low temperature, high salt concentra-
tion) may promote the correct folding and the crystal formation of 
the mutant polypeptide even if it has decreased thermostability. 
 In recent years it has become evident that F508 causes altera-
tions in NBD1 dynamics. First, local alterations were demonstrated 
experimentally in the region where the F508 is localized, employ-
ing backbone amide H+/D+ exchange measured by mass spec-
trometry [114]. These measurements revealed that F508 increases 
the backbone dynamics at residues 509-511 and in parallel, crystal 
structures showed surface exposure of V510 in the mutant, which is 
buried in the wild type protein. Close to this region, the linker be-
tween the - and -subdomains (residues 492-499) showed in-
creased mobility in the mutant compared to the wild type protein in 
a molecular dynamics study [115]. This enhanced dynamics also 
resulted in an increase in exposed surface that may promote the 
recognition and degradation of the mutant protein by the quality 
control system in the cellular environment. Interestingly, the re-
moval of the regulatory insertion (RI; residues 404-435), which is 
present exclusively in the CFTR NBD1 and is highly dynamic 
[81,113,114], increased the functional expression of F508 CFTR 
[116]. Although the role of this region is unknown and its removal 
does not alter channel function in oocytes [117], the deletion of the 
RI increases the cell surface protein level and the half-life of the 
mutant F508 protein. Moreover, RI removal also restores domain-
domain interfaces, nucleotide binding in NBD1, and channel func-
tion to the wild type level. Since the RI region is dynamic and its 
deletion increases the mobility of the F508 region, it was proposed 
that these two regions are dynamically coupled. However, analysis 
of discrete molecular dynamics simulations indicates that this is not 
the case [116]. In contrast, movements of the F508 region correlate 
with the dynamics of the -subdomain. This correlation is lost in 
F508 and can be partially restored by RI deletion. These results 
suggest that some of the RI conformations interfere with the dy-
namic coupling between the F508 loop and the -subdomain. A 
potential pharmacological approach could be to develop a small 
molecule to restrict the dynamics of RI that may restore the cou-
pling between these regions and thus rescue the folding and expres-
sion of the mutant protein. Indeed, the intrinsic large structural 
fluctuations of NBD1 may be the origin of the enhanced effects of 
F508 in humans compared to other species, where several flexible 
regions contain Pro residues restricting the available conformational 
space [118]. 
 Since alterations in dynamics are responsible for the impaired 
processing and function of the mutant CFTR, the so-called rescue 
mutations, which are introduced at other locations of NBD1 (at 
I539 [119], F494/Q637 and F429/F494/Q637 [120] and R553 
[121]) and partially restore the functional expression of the F508, 
act most likely by restoring the dynamic coupling between different 
parts of F508 NBD1 to the wild type level. These rescue muta-
tions and the observation that the binding of ATP promotes the 
vectorial folding of CFTR NBD1 [122] show the validity of design-
ing small molecules that interact with the intracellular NBD and 
restore the folding pathway. ATP binding most likely shifts the 
dynamic ensemble of nascent chains at a critical step of the co-
translational folding promoting the availability of a conformation 
critical for the further steps of correct folding. Similarly, a water 
soluble substrate (intracellular glutathione) interacting with the 
cytoplasmic parts of MRP1 rescues the folding deficient F728 
MRP1, which is analogous to the F508 CFTR [123]. Interestingly, 
affecting the available conformational space in a part most distant 
than the nucleotide binding domains also seems to be a valid ap-
proach to rescue the mutant channel. The Y490 MDR1, analogous 
to F508 CFTR, can be rescued by the interaction of a hydrophobic 
drug, cyclosporine A [124]. Chemical cross-linking experiments 
confirmed that cyclosporine A binds to the TMDs promoting the 
native TM helix conformation. Moreover, at the same time the 
TMD/NBD interface and the native conformation of NBD are also 
restored, indicating a strong dynamic coupling between the trans-
membrane domains and cytosolic parts [124]. 
 In chronic inflammatory bile duct diseases the expression and 
function of hepatobiliary ABC transporters requires stimulation 
[125] that could be achieved based on similar principles as de-
scribed above for CFTR. Mutations that alter the substrate specific-
ity of multidrug transporters expressed at physiological barriers 
(e.g. intestine, blood-brain barrier) can seriously alter the pharma-
cokinetics (such as absorption, secretion) of medicaments. This 
usually leads to increased accumulation of xenobiotics in the body, 
also increasing the side effects of the particular treatment [126]. If 
the substrate specificity is defined by dynamics as described in 
Section 2.A, a small molecule corrector could shift the dynamic 
ensemble back to wild type and allow treatment with regular doses 
that were developed and tested in patents carrying wild type alleles.  
 This complexity of dynamic coupling in ABC transporters has 
major implications for drug development. Allosteric modulators of 
dynamics would allow the application of small molecules acting in 
the membrane region to correct the folding of an intracellular do-
main. The above examples also show that altered dynamics of a 
certain region is not fully responsible for the malfunction of a pro-
tein. Moreover, it has been shown that F508 alters NBD1 both 
kinetically and thermodynamically and correction any of these de-
fects results only in partial rescue of the mutant channel [127]. 
Therefore non-conventional multi-target drugs may be developed to 
allow the functional rescue of ABC proteins. This type of drugs 
should target different regions in the protein, thus even actions with 
partial efficiency may result in full restoration of protein function 
based on network theory [128-130]. These strategies can also be 
applied to other ABC transporters with diminished folding and 
altered dynamics, such as ABCA4 in macular degeneration 
[102,103] or ABCC6 in pseudoxanthoma elasticum [104]. 
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3. NETWORK DESCRIPTIONS OF CONFORMATIONAL 
AND PROTONATION CHANGES 
 To understand and modulate the dynamical coupling between 
regions of proteins, novel theories and tools of networks can be 
applied. In this Section first we give a brief summary of the defini-
tions of networks related to protein structure and dynamics, such as 
protein structure networks, protein sectors, Gaussian network mod-
els, elastic network models, normal-mode analysis, networks based 
on the correlations of residue fluctuations and conformational net-
works. We highlight the use of these network models to predict hot-
spots involved in ligand or protein binding, as well as in the trans-
mission of conformational changes. Finally, the applications of the 
network approach in the assessment of protonation changes and 
drug design are summarized. 
3.A. Network Descriptions of Protein Structure and Dynamics 
 Protein structure networks (which are recently more and more 
referred to as residue interaction networks, RIN-s) represent the 
molecular basis of more sophisticated cellular networks, such as 
protein-protein interaction or signaling networks. In most protein 
structure network representations not the individual atoms are the 
nodes of the network, but due to the concerted movements of amino 
acid side-chains, amino acids of the protein represent network 
nodes. Network edges are related to the physical distance between 
side-chains, in most cases measured between C or C atoms. In 
some representations the centers of mass of the side chains are cal-
culated, and distances are measured between them. Edges of un-
weighted protein structure networks connect amino acids having a 
distance below a cut-off. The cut-off distance is usually between 4 
to 8.5 Å [20-23,25-27,131-134]. Recently a detailed study was pub-
lished comparing the effect of various C-C contact assessments, 
such as the atom distance criteria, the isotropic sphere chain and the 
anisotropic ellipsoid side-chain models, as well as of the selection 
of various cut-off distances. The atom distance criteria model 
proved to be the best, and had a moderate computational cost. The 
best amino acid pair specific cut-off distances varied between 3.9 
and 6.5 Å [135]. Protein structure networks often have weighted 
links instead of distance cut-offs, where the edge weight is usually 
inversely proportional to the distance between the two amino acid 
side-chains. Covalent bonds may be included or excluded in the 
network representation [20-23,25-27,131-134].  
 Protein structure networks are “small worlds” meaning that 
their nodes are separated by only a few edges on average, and the 
network diameter grows only logarithmically with increasing num-
ber of nodes, i.e. with the size of the protein. This small-worldness 
is very important in the fast transmission of conformational 
changes, since it means that all amino acids can reach each other by 
taking only a very little number of steps. The degree distribution of 
protein structure networks is usually not scale free. This means that 
we may find much less large hubs (amino acids surrounded by a 
large number of neighbors) than in other networks. However, the 
existing smaller hubs play an important role in protein structures, 
e.g. these ‘micro-hubs’ were shown to increase the thermodynamic 
stability of proteins [22,25,28,131,136-141]. 
 The absence of large hubs in protein structure networks is pri-
marily due to the limited changes of protein structures. These 
changes are limited in the sense that amino acids may not just leave 
their original neighbors, and associate with another neighborhood, 
since the covalent bonds do not allow such a gross reorganization. 
Large changes of network environment are rather usual in networks 
at higher hierarchical levels. Proteins are often transported from one 
cellular compartment to the other, where they bind to a different set 
of other proteins. Several proteins, such as “date hubs” [142] are 
known for notoriously promiscuous behavior, i.e. for changing their 
binding partners rather often. In this way to the same binding site a 
large number of different neighbors may bind at different time 
points, which - at larger time windows, or observing larger popula-
tions, as high-throughput experiments usually do - appears as the 
existence of large hubs having a large number of neighbors. As 
another example, several hundreds of acquaintances of the Reader 
on Facebook do not mean that the Reader is able to conduct a paral-
lel information exchange with all of them at the same time (if doing 
that right now the Reader probably would not be reading this pa-
per). In agreement with the above considerations, recent investiga-
tions reported large changes in the structure of mobile telephone 
call networks, when the time window of call aggregation was 
changed [143]. In summary, being a hub is a relative measure, 
which often depends on the time window of observation. The time 
window dependence is prevalent in networks where the node 
neighborhood may be changed, like in social networks. Thus the 
‘mega-hubs’ of social networks are sequential hubs, unlike the ‘mi-
cro-hubs’ of protein structure networks, which are parallel hubs. 
 Protein structure networks have modules (or in other words, 
which are mostly used in social sciences: network communities). A 
network module describes a group of nodes, which are connected 
(or in a recently used definition: exchange information) more 
densely with their neighborhoods than the entire group. Modules of 
protein structure networks quite nicely locate protein domains [26, 
27, 139,144-150]. 
 Recently protein structure networks have been used to predict 
key functional residues, hot-spots, substrate and protein binding 
areas as high centrality regions (hubs, closeness and betweenness 
centralities) but having a lower clustering coefficient [151,152]. 
Some of these positions nicely correspond to the definition of ‘crea-
tive nodes’ resembling the structural holes creative persons fill in 
social networks [153]. Creative node positions display a discrete 
dynamic behavior [32,33] and were termed as independent dynamic 
segments [69]. Importantly, since there is a whole family of net-
work centrality measures [154], and network dynamics should also 
be taken into account, the identification of key functional residues 
will certainly be enriched and improved further in the future. The 
above approaches can also be used in the identification of drug 
binding sites as we will discuss in Section 3.D. in more detail. As 
an example of these utilizations, protein structure network position-
based additional scores significantly improved the rigid-body dock-
ing algorithm of pyDock [152]. 
 In the last few years automated servers and analysis methods 
have been established to convert Protein Data Bank 3D protein 
structure files into protein structure networks. The RING server 
(http://protein.bio.unipd.it/ring) [155] gives a set of physico-
chemically validated amino acid contacts, and imports it to the 
widely used Cytoscape platform [Shannon et al., 2003] enabling 
their further analysis. Using this server additional secondary struc-
ture-, solvent accessibility-, and experimental uncertainty-based 
factors may be combined with information on residue conservation, 
mutual information and residue-based energy scoring functions. 
Doncheva et al. [132,133] published a set of papers developing a 
specific assessment tool-kit for protein structure networks, RINa-
lyzer (http://www.rinalyzer.de) linked to Cytoscape, and comple-
mented with a protein structure determination module, RINerator 
(this latter stores the pre-determined protein structure networks of 
Protein Data Bank 3D protein structure files at 
http://rinalizer.de/rindata.php). The RINalyzer program has also 
been linked to NetworkAnalyzer allowing the examination of resi-
due interaction networks derived from protein structures, and the 
comparison of protein structure networks. 
 Evolutionary conservation patterns of amino acids in related 
protein structures identified protein sectors [156]. Protein sectors 
are sparse networks of amino acids spanning a large segment of the 
protein. Protein sectors are collective systems operating rather in-
dependently from each other. Segments of protein sectors are linked 
to many surface sites distributed throughout the entire structure, are 
correlated with protein movements linked to enzyme catalysis and 
sector-connected surface sites are often places of allosteric regula-
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tion [157]. Sectors emerge as an ‘intra-protein wiring’ transmitting 
perturbations between important sites of substrate, ligand, protein, 
RNA, or DNA binding. A similar concept has been published by 
Jeon et al. [158], who determined that co-evolving amino acid pairs 
are often clustered in flexible protein regions. 
 At the fastest level protein dynamics is usually described by the 
ensemble of atomic vibrations. Conformational changes occur at a 
slower dynamical level. While current methods of protein structure 
networks usually use them for the structural description of proteins, 
the statistical mechanics approaches of Gaussian network models, 
elastic network models and normal-mode analysis are mostly used 
to assess protein dynamics. In elastic network models a harmonic 
potential is used to describe pairwise interactions between C at-
oms only, or among all atoms, forming a spring network [23,28-
37]. An increasing number of publications use correlation networks 
of ensemble-based models of the native state, residue position fluc-
tuations, or covariance of NMR chemical shift changes [159-161]. 
These models helped the localization of hot-spots for ligand bind-
ing, and the identification of information pathways in proteins. 
 Conformational networks describe all possible conformations of 
a given protein, where nodes are the individual conformations the 
protein may adopt, and edges represent the possible transitions 
between these conformations [23,37,69,162]. The possible interre-
lationships between protein structure networks and conformational 
networks have not been explored so far and represent a truly excit-
ing area of further studies. 
3.B. Network Representations of Conformational Changes 
 Conformational changes seldom ‘just happen’. Most of large-
scale conformational changes have to be provoked. Provoked by the 
binding of a substrate, ligand or drug, or another macromolecule be 
it a protein, RNA, DNA or membrane, or by a change in the phys-
ico-chemical environment, such as a change in pH, molecular 
crowding, hydrophobicity of the surrounding medium, change in 
hydrogen bond structure, etc. The above considerations also predict 
that, if conformational change happens, it is usually not a smooth 
and straightforward process. Indeed, a rather long time ago ‘protein 
quakes’ have been described, i.e. a discontinuity of the conforma-
tional change was discovered [163]. A conformational change is 
often an avalanche of incremental, small changes in chemical bond 
configurations. If the first of these bond-rearrangements triggers the 
second, which triggers the third, we may finally arrive at a highly 
concerted, highly cooperative, but at the same time, at the level of 
the individual molecules, highly unpredictable process. The protein 
quake leads to a conformational change if it was able to cover the 
whole length of the trajectory leading to the appreciable change, 
and was not stalled somewhere in the middle, or swung back to the 
original position again. 
 In the last years many databases on conformational changes, 
like DynDom (http://fizz.cmp.uea.ac.uk/dyndom/enzymeList.do), 
ASD (http://mdl.shsmu.edu.cn/ASD/) have been assembled 
[164,165]. DynaSIN (http://archive.gersteinlab.org/proj/DynaSIN/) 
allows the investigator to assess the effects of conformational 
changes on the protein-protein interaction network [166].  
 Binding of the conformation-provoking agent requires a gross 
reorganization of interactions (including desolvation), which is a 
source of frustration and conflict in need of efficient mediation to 
accomplish binding [167-171]. Mediation of conflict may be pro-
vided by  
1) key residues of protein structure, which may be positioned at 
inter-modular boundaries, [170] and which we called inde-
pendent dynamic segments [32,33,69,131,153];  
2) transient bonds (e.g. transient, non-native hydrogen bridges) 
[170,172,173];  
3) water [162,170,171] and by 
4) molecular chaperones [162].  
 It is important to note that all the above forms of mediation are 
rather transient. Independent dynamic segments [32,33,69,131] may 
lose their independence as binding proceeds. Before binding, by 
definition, independent dynamic segments have separate dynamics 
from the rest of the protein. Binding-induced stabilization may 
coalesce the motion of these key protein segments with neighboring 
domains. (In fact, this may contribute to the binding-induced stabi-
lization of the novel structure.) Water molecules are expelled by the 
binding-induced, gradual desolvation [167-171]. Chaperones re-
lease their targets aiding the accomplishment of protein complex 
formation. In all cases the decrease of mediation is gradual, and 
occurs in concert with the decreasing need for mediation of the 
conflicts. All the above events are occurring at a rather large scale if 
the binding partner is a macromolecule, like a protein. However, 
most of them play a role, if the binding partner is a small molecule, 
like a substrate, ligand or drug, or the conformational change was 
triggered by even smaller individual triggers posed by the change in 
the environment. 
 As binding proceeds not only the conformation of the protein is 
changing (accompanied by the changing position of the protein on 
its energy landscape) but the approaching binding partner also 
changes the shape of the energy landscape itself. As the protein is 
approached by its binding partner, electrostatic and water-mediated 
hydrogen-bonding signals emerge, and they increasingly change the 
protein’s environment altering its energy landscape [69,162,174]. 
The encounter of the protein with its binding partner involves a 
large number of conditional steps, where the next step of the en-
counter by the protein depends on a preceding change of its partner 
and vice versa. These concerted, conditional steps are not that well 
developed if the binding partner is a small and rigid molecule, like a 
substrate, ligand or drug, since the rigid binding partner does not 
have a lot of degrees of freedom to adapt. However, if the binding 
partner itself is also a protein or another macromolecule (RNA, 
DNA), the process becomes similar to ‘wooing’, and may be called 
an ‘interdependent protein dance’ [69,162]. 
 The mutually conditional, stepwise encounter and selection 
steps can be modeled as a series of common social dilemma games. 
In the hawk-dove game model the rigid binding partner is the hawk, 
while the flexible binding partner is the dove, the payoff is the de-
crease of the free energy of the unbound state. The Nash equilib-
rium in the case of a hawk/dove encounter corresponds to an in-
duced fit type scenario, where the conformational change of the 
dove is much larger than that of the hawk. This is a rather common 
case if a protein binds to a ligand. Here the protein is the dove, and 
the ligand is the hawk. The ligand (hawk) is the winner as com-
pared to a flexible protein (a dove). For the rigid ligand the enthalpy 
gain of binding is not accompanied by an entropy cost as opposed 
to the more flexible protein, since the latter loses several degrees of 
freedom during binding. The ultimatum game provides another 
representation of the same scenario resembling the induced-fit 
mechanism. Here the two binding partners want to share the free 
energy decrease as the resource. The first, rigid partner proposes 
how to divide the sum between the two partners, and the second, 
flexible partner can either accept or reject this proposal [69,162, 
174-176]. 
 We note that the duality of the start state and the end state in-
ferred by the concept of conformational change is not unique to 
protein structures, but can be generalized to all complex systems. A 
‘conformational change’ starting from a rather integrated structure 
under normal conditions and changing to a rather modular structure 
upon stress was recently observed in the yeast interactome. 
Changes in modular structure were shown and proposed to be a 
general mechanism of adaptive processes. In a neural network 
model it was shown that a modular structure of the neural network 
gives a faster convergence of the neural network behavior to quasi-
stable states (attractors). This corresponds to the above assumption 
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that a certain level of modularity accelerates the adaptive changes. 
Bimodal behavior is characteristic to many types of networks in-
cluding protein-protein interaction networks, metabolic networks, 
social networks and last, but not least protein structure networks 
[131,149,177-179]. The emergence of preferred (often bimodal) 
final states has been demonstrated by several studies calling the 
preferred states attractors in the state space (corresponding to a 
multidimensional energy landscape in case of molecular or cell 
rearrangements). Cancer was proposed to be a divergence from the 
normal trajectories representing the actual changes of cells, which 
had a smaller barrier due to mutations or epigenetic changes allow-
ing malignant transformation. It turned out that between 80 and 200 
changes in gene transcription must contribute to complete this proc-
ess. Approach of the attractors representing various stable states of 
the cells was proposed to have multiple trajectories. Trajectories 
can be deconvoluted to gene-encoded regular trajectory segments 
and to the stochastic variations of these regular trajectory segments 
caused by the actual, unique environmental factors [180-182]. For 
the transition from one attractor to the other (like during the differ-
entiation of hematopoietic progenitor cells into the eyrthroid or 
neurophil lineages) networks have to acquire a transient flexibility 
to allow the transition to occur [183]. Please note that many of the 
above considerations in other, mostly cellular systems hold to the 
conformational changes of proteins. The multiple pathways con-
verging at the other attractor, the transiently increased flexibility, 
the importance of modular structure have already been uncovered in 
examining the mechanism of conformational changes as we will 
show below, or provide exciting research areas for future studies. 
 The mechanism of conformational changes attained a lot of 
attention in the last century. In these studies quite often allosteric 
interactions have been assessed. The reason of this is that in allos-
teric interactions the final effect of the allosteric ligand to enzyme 
activity could be assessed quite readily. In recent years precise ana-
lytical methods for the dynamics of protein structures became 
available, which allowed the analysis of conformational changes 
which were not linked to changes in an enzyme activity [69-72,184-
186]. 
 The first step of binding is quite often the formation of transient 
encounter complexes. These complexes are mostly stabilized by 
electrostatic forces, have a small, planar contact area in the range of 
only a few Å2, and cover a larger segment (e.g. 15%) of the total 
surface area around the binding site as revealed by paramagnetic 
relaxation enhancement experiments [187,188].  
 In the following step ‘anchor residues’, i.e. residues stabilizing 
the transient encounter complex formed in the first step, often play 
an important role. Anchor residues have a similar position as in the 
bound state, and have a large surface area in the range of 100 Å
2
. 
Binding to anchor residues is followed by the completion of bind-
ing involving several ‘latch residues’ giving a further stabilization 
of the complex [189].  
 Anchor and latch residues (positioned often very close to the 
binding site) are by far not the only protein segments involved in 
binding partner-induced conformational changes. Hinges (located 
often at distant positions from the binding site) were proposed to 
play a decisive role in these conformational transitions [172]. Criti-
cal nodes between communities of amino acid networks were also 
shown to play a key role in the reorganization of the protein struc-
ture [23,145,153,190]. Recently elastic network analysis uncovered 
the existence of specific protein segments having ‘discrete breather’ 
behavior. These segments accumulate and dynamically exchange a 
large portion of overall energy, and are often located very close to 
the binding or catalytic sites [32,33]. We called these one to a few 
amino acid long parts of protein ‘independent dynamic segments’ to 
emphasize their distinct behavior [69]. Hinges, critical nodes and 
independent dynamic segments significantly overlap, since inde-
pendent dynamic segments are located in stiff, hinge-type regions 
of proteins, and both may often be positioned at inter-modular 
boundaries [23,32,33,69,145,153,172,191]. A key role of specific 
regions of co-evolving amino acids called ‘protein sectors’ in the 
transmission of conformational changes was also suggested [157]. 
Currently it is not known to what extent hinges, critical nodes, in-
dependent dynamic segments and protein sectors define the same 
protein segments. 
 As we described above, the inventory of individual protein 
segments involved in the orchestration of conformational changes 
has been grossly expanded in the last few years. However, the se-
quence of dynamic events, how they interact, and how they actually 
cause the change, is still not completely understood. A series of 
conformational distorsions has been proposed more than ten years 
ago to mediate the conformational change [160]. Pathways of con-
formational change propagation (mostly in allosteric changes where 
both the trigger site and the effector site can be easily identified) 
have been uncovered using protein structure networks, Gaussian 
network models, Markov random walks, correlations in residue 
fluctuations, or co-variance of NMR chemical shifts. Propagation 
pathways were small-worlds providing rather short routes between 
the trigger and the effector sites and often involved multiple trajec-
tories converging at inter-domain boundaries [159,161,190,192-
199].  
 Current molecular mechanisms of conformational changes in-
clude the propagation of a ‘frustration front’ [37], where frustration 
means that certain residues have accumulated a tension, which 
prompts their unusually large dislocation, once the allosteric ligand 
triggered the release of this tension. A recent study [200] on 51 
pairs of proteins in active and inactive state using the FIRST algo-
rithm [31] found that rigid paths connect the effector and catalytic 
sites in 69% of the data set. An increased rigidity in active state 
relative to the inactive state has also been observed. However, 31% 
of the studied structures failed to follow this trend [200]. The uncer-
tainties prompt further studies of this exciting field.  
3.C. Network Analysis of Protonation Changes 
 Protonation changes have seldom been studied directly using 
protein structure networks. Most protonation-related studies dealt 
with hydrogen bonding networks, where the word “network” is 
used in a different context, like elsewhere in this review. Hydrogen 
bonding ‘networks’ consist of a rather few nodes, seldom reaching 
ten. These very tiny networks still play a paramount role in the 
mechanism of active centers of several enzymes and in many water-
mediated conformational changes, such as those of the activation of 
family A G-protein-coupled heptahelical receptors [201] and of 
mineralocorticoid receptors [202], as well as in the Ca-decrease-
dependent activation of the tobacco mosaic virus protein [203]. The 
midpoint reduction potential of cytochrome c is also controlled by a 
hydrogen bond network [204]. Interestingly, a water molecule plays 
an important role in the stabilization of the interaction of HIV-1 
protease with its inhibitors acting as a collision buffer, and helping 
the re-formation of broken hydrogen bonds [205]. The activity of 
subtilisin and chymotrypsin inhibitor 2 also depends on an exten-
sive hydrogen bonding network [206,207]. A particularly nice ex-
ample of the involvement of protonation-related networks is the 
activation of native rhodopsin, which proceeds via the protonation 
of the retinal Schiff-base, where coupling of several protonation 
switches has been shown [208-210]. Re-design of hydrogen bond 
network may grossly extend the specificity between the proper 
substrate (drug) and its binding protein [211]. 
 Protonation changes of the bacterial Resistance-Nodulation-
Division (RND) family drug/proton antiporters led to gross con-
formational rearrangement mainly at charged residues in the trans-
membrane domain helping the extrusion of the drug bound to the 
periplasmic domain of the RND transporter [212]. With the RND 
proton antiporter protonation-driven conformational changes are 
more than expected. Whether such a mechanism might exist in 
ABC transporters is a question of interesting future studies. 
4164    Current Pharmaceutical Design, 2013, Vol. 19, No. 23 Hegeds et al. 
3.D. Pharmacological Applications of Protein Structure Net-
works 
 Protein structure networks have been involved in many steps of 
drug design from the determination of drug binding sites to the 
identification of novel drug targets. In this review we give only a 
brief summary of the most important applications. 
 The first step to identify drug binding sites is to find appropriate 
cavities on protein surfaces. Though excellent programs exist to 
serve this purpose such as the SCREEN [213], which also takes into 
account physico-chemical, structural and geometric properties of 
the cavity, protein structure networks have seldom been used yet for 
this purpose. 
 Quantitative structure-activity relationship (QSAR) methods 
have an unparalleled importance in the identification of optimized 
drug binding. Protonation states may be incorporated into usual 3D 
receptor QSAR methods as a 4
th
 dimension (4D QSAR) leading to 
more accurate results [214,215]. As an additional source, PDTD 
(http://www.dddc.ac.cn/pdtd/) is a web-accessible protein database 
for drug target identification, docking a small molecule to a reposi-
tory of proteins with known 3D structure [216].  
 Binding of a large number of drugs, or drug-like molecules to 
proteins can be studied by wet lab or in silico experiments. An edu-
cating example for the former is the study of Clemons et al. [217], 
where a diverse collection of small molecules was bound to 100 
diverse proteins. Increasing the content of sp
3
-hybridized and thus 
stereogenic atoms improved binding selectivity and frequency. An 
in silico study showed that druggable sites comprised a cluster of 
binding hot-spots having a concave topology with a pattern of hy-
drophobic and polar residues. Importantly, druggable sites had a 
conformational adaptivity to allow the hot-spots to expand, and 
accommodate a ligand of drug-like dimensions [218]. 
 Network properties of drug-binding sites are rather similar to 
those of active centers and of the residues involved in the propaga-
tion of conformational changes detailed in Section 3.B. Residues of 
heme-binding regions were found to be generally associated with 
hubs, high closeness and betweenness centralities together with a 
low clustering coefficient [151]. The interesting study of Asses et 
al. [219] extended the known properties of the catalytic site of the 
Met-kinase, an interesting target for anticancer drug design. The 
ATP binding site of this kinase displays an unusually high plastic-
ity, which may allow its selective targeting. Previously unknown 
conformations of the site were modeled and serve the design of 
novel Met-selective drug candidates.  
 Recently a number of protein/ligand or protein/drug databases 
were established. CREDO (http://www.cryst.bioc.cam.ac.uk/credo) 
lists protein/ligand interactions, representing contacts as structural 
interaction fingerprints [220]. DrugBank (http://www.drugbank.ca) 
is a dataset of the interactions of more than 4,100 drugs and more 
than 14,000 proteins [221]. STITCH 3 (http://stitch.embl.de) offers 
an aggregated database of the interactions over 300,000 chemicals 
and 2.6 million proteins [222]. Dr. PIAS (http://www.drpias.net) 
assesses whether a protein-protein interaction is druggable as a 
target for small chemical ligands [223]. Besides the assessment of 
the binding profile of new drug candidates, the use of protein/drug 
databases may lead to the discovery of unexpected novel targets of 
known drugs, as was the case when anti-Alzheimer drugs have been 
assessed [224].  
 Designing drugs for targets with similar active sites is challeng-
ing due to low specificity of the molecules on the chosen target. 
Construction and analysis of binding-site similarity networks can be 
helpful to identify proteins whose active sites are different enough 
to be targeted selectively. Using 491 human protein kinase se-
quences, Huang et al. [225] constructed similarity networks of 
kinase ATP binding sites. The selective inhibition of kinases that 
are in small clusters of the network having only few links to other 
nodes, is more likely than of those having a large number of links in 
large clusters, hence, being similar to many other kinases. This 
approach to selective inhibition is consistent with recent experimen-
tal results targeting tyrosine kinase EphB4 that belongs to a small, 
highly linked subfamily of kinases with few links to other kinases 
[225].  
 Allosteric drugs (binding to allosteric effector sites) are consid-
ered to be better than orthosteric drugs (binding to active centers) 
due to three reasons. First and foremost: allosteric drugs often have 
less side effects than orthosteric drugs due to the larger variability 
of allosteric binding sites than that of active centers. Second: they 
allow the modulation of drug therapy effects in a tunable fashion. 
Third: they mostly act only when the endogenous ligand is bound, 
i.e. exactly at the time when the cell needs their action. They are 
non-competitive with the endogenous ligand therefore their dosage 
can be low [226,227]. Allosteric drugs may not need to bind to ‘in 
vivo’ allosteric sites, but may also bind to allosteric sites which are 
not used by natural ligands. The intra-protein propagation pathway 
of the allosteric effect becomes increasingly known as we summa-
rized in Section 3.B. and as it is described in the review of De 
Benedetti and Fanelli [195]. Using this knowledge novel allosteric 
drug binding sites might be found on several proteins. As a poten-
tial novel source for such studies, non-synonymous single nucleo-
tide polymorphisms (nsSNPs, SAPs) were found to be associated 
with diseases if the changed amino acid was a hub, or had a high 
centrality in the protein structure network. The neighboring residues 
around the SAP site quite strongly determined its association with 
disease [228]. Disease-associated SAPs may often be a part of the 
propagation pathways of allosteric effects. Their surface-associated 
subset may be an interesting dataset to assess the existence of novel 
allosteric drug binding sites. 
 The concept of allosteric drugs can be broadened to allo-
network drugs, whose effects can propagate across several proteins, 
to enhance or inhibit specific interactions along a pathway. Drug 
action propagates from the original binding site to protein-protein 
interaction network (interactome) neighbors in a non-isospheric (i.e. 
not uniform to all distances), highly specific manner. Binding sites 
of promising allo-network drug targets are not parts of ‘high-
intensity’ intracellular pathways, but are connected to them. Thus 
allo-network drugs can achieve specific, limited changes at the 
systems level achieving fewer side effects and lower toxicity than 
conventional drugs. Allosteric effects can be considered at two 
levels: (1) stepwise events restricted to the neighbors or network 
module of the originally affected protein; (2) propagation via large 
cellular assemblies over large distances (i.e. hundreds or even thou-
sands of Angstroms) [227].  
 For the identification of allo-network drugs first the interactome 
has to be extended to atomic level resolution. For this, docking of 
3D protein structures and the consequent connection of their protein 
structure networks are needed. A successful candidate for the inter-
protein allosteric pathways involved in allo-network drug action 
disturbs the network perturbations specific to a disease state of the 
cell at a site distant from the original drug-binding site. Perturbation 
analysis [174,229] applied to the atomic level resolution of the in-
teractome in combination with disease specific protein expression 
patterns may help the identification of such allo-network drug tar-
gets. We may use a number of centrality measures including pertur-
bation-based, or game-theoretical assumptions to find the level of 
importance of various proteins and pathways in the cellular network 
[154,229]. By the analysis of directed networks, such as signaling 
or metabolic networks, we may construct a tree-like hierarchy [230] 
to assess the importance of various nodes, or we may find driver 
nodes controlling the network by the application of a recently pub-
lished method [231]. A general strategy for the identification of 
allosteric sites may involve finding large correlated motions be-
tween binding sites. This can reveal which residue-residue corre-
lated motions change upon ligand binding, and thus can suggest 
new allosteric sites [232] even in integrated protein structure net-
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works of mega-complexes. Reverse engineering methods [233] 
allow us to discriminate between ‘high-intensity’ and ‘low-
intensity’ communication pathways of cellular networks, and thus 
may provide a larger safety margin for allo-network drugs. In this 
way a large number of novel and specific action sites can now be 
proposed as potential targets of allo-network drugs.  
 A specific extension of orthosteric, allosteric and allo-network 
drugs are multi-target drugs, which act on multiple target sites. 
Multi-target drugs multiply the number of pharmacologically rele-
vant target molecules by introducing a set of indirect, network-
dependent effects. Many conventional drugs, like aspirin are multi-
target drugs. Combination therapies also use the effect of multi-
target action. Simultaneous binding to multiple targets requires 
mutual compromise in binding accuracy and results in a lower af-
finity than the precise targeting of a single protein. Our earlier stud-
ies showed that multiple actions with lower affinity (50% efficient) 
may result in similar effects at the whole network level than a 100% 
efficient targeting of the most important network hub, even if only 
3 to 5 proteins are targeted [128]. Designing multi-target drugs is a 
challenging but not a formidable task to solve. Moreover, the low-
affinity binding of multi-target drugs eases the constraints of drug-
gability and significantly increases the size of the druggable pro-
teome [129,130]. 
 How to find proper multi-target sets? All the above considera-
tions for allo-network drugs can be extended allowing multi-target 
design. Multiple perturbations may be assessed [174,229], central-
ity, hierarchy, controllability and co-variance measures [154,231, 
232] can be calculated in a multi-nodal fashion. Xie et al. [234] in 
an attempt to discover drugs that are able to inhibit multiple targets 
constructed similarity networks of protein binding sites. The 
authors generated a network of 232 non-redundant M. tuberculosis 
proteins using the sequence-order-independent profile-profile 
alignment (SOIPPA) algorithm, and identified the 18 mostly con-
nected proteins. Identifying clusters of proteins with similar binding 
sites could be another starting point for designing multi-target 
drugs. 
 Several network considerations are seemingly unrelated to the 
problem of multi-target drug design, but could still be used quite 
efficiently to solve this complex problem. We just give two recently 
published examples here. Morris and Barthelemy [235] examined 
the transport between multiple sources and sinks in a coupled net-
work, which is a system where two interdependent networks are 
tightly linked together. They found that the number of sinks deter-
mines the optimal routes from sources, which is the minimum 
shortest path if the number of sinks are low, but congestion phe-
nomena occurs, and necessitates a more complex treatment when 
the number of sinks increases. These considerations may well be 
used when designing multi-target drugs. An interesting paper gave 
an algorithm to describe the controllability of leader-follower net-
works of multi-agents systems [236]. Though the systems they 
covered included robotic networks, flocking birds, sensor coverage 
and others, the method might also be useful in multi-target drug 
design. 
4. CONCLUSION AND PERSPECTIVES 
 In this concluding Section first we give a few examples how the 
network approach might be used in the assessment and modulation 
of ABC transporter functions. From the examples above it is clear 
that the proper folding, expression, and function of ABC transport-
ers is maintained by and is highly sensitive to dynamics of the 
polypeptide chain. The different dynamics of various parts of a 
protein exist not as an individual units but exhibit highly coupled 
motions. The analysis of the coupling of these dynamic units em-
ploying a network approach may help to understand the mechanism 
of function and to identify drug targets. 
 For example, it became evident that targeting F508 CFTR at a 
single location to improve either its kinetic or thermodynamic prop-
erties rescued the mutant channel only inefficiently [127]. Based on 
common sense, all properties must be corrected to fully restore the 
functional expression of the mutant protein. However, principles of 
network theory suggest that partial modulation of multiple dynamic 
nodes in the protein will have a greater effect on the network (struc-
tural and dynamic units of the protein) than the complete modula-
tion of one of the nodes (kinetics or thermodynamics) [128,129]. 
 The rescue of Y490 MDR1 by a hydrophobic substrate sug-
gests that the dynamics of the transmembrane regions is strongly 
coupled to the nucleotide binding domains [124]. This also indi-
cates that the design of small molecules acting in the transmem-
brane regions is rational to correct the folding and dynamics of 
intracellular domains without the need for the corrector molecule to 
enter the cytoplasm. In order to avoid designing substrate-like small 
molecules that would interfere with the transport of the physiologi-
cal substrate of transporters, modulation at allosteric sites would be 
desirable. A network approach can be applied to identify dynamic 
units which are also allosteric sites and connections between them. 
Such a network map would enable one to select the appropriate unit 
(node) whose dynamics is to be modulated in order to functionally 
rescue the protein. A similar network approach can be used to shift 
the dynamic ensemble of a mutant with altered substrate specificity 
to the ensemble characteristic of the wild type protein to avoid side 
effects of drugs tested in individuals expressing the wild type trans-
porters. 
 In summary, in this review we detailed the importance of syn-
thesis of structural, dynamic, computational and experimental in-
formation on ABC proteins to design and improve strategies modu-
lating their functional expression. We showed how the dynamics of 
different parts of ABC proteins are coupled and the importance of 
studying intramolecular interactions using network approach. Now 
we will highlight the major points where we predict progress in this 
pharmacologically exciting expanding field: 
• detailed comparison of various network descriptions, such as 
protein structure networks, protein sectors, Gaussian network 
models, elastic network models, normal mode analysis, net-
works based on the correlations of residue fluctuations and 
conformational networks will bring a much detailed under-
standing of both protein structure and function; 
• detailed analysis of conformational change space in terms of 
trajectories and attractors will greatly benefit from the network 
approach in the future; 
• refined modular structure of networks related to protein struc-
ture and function will certainly give a novel understanding of 
structure/function relationships; 
• the identification of key functional residues will benefit from 
the recent introduction of novel structural and dynamic net-
work centrality measures; 
• the mechanism of conformational changes is far from being 
understood, here network studies may bring novel solutions 
and understanding; 
• protonation changes have only been seldom covered by net-
work studies so far;  
• several pharmacological applications remain uncovered, here 
network approach may lead to the discovery of novel drug 
binding sites and drug targets. 
 All the above considerations will bring new areas to uncover 
ABC transporter action and for its pharmacological modifications. 
Comparison of various conformations of ABC proteins using global 
network invariants will certainly help the understanding of ABC 
transporter function. Comparison of nodes in different conforma-
tions having a specific network position, such as those described by 
Guimera et al. in their paper on network cartography [237] will 
extend our knowledge on structure/function relationships. Studies 
on the modular structure [149,154] of ABC transporter protein 
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structure networks (as illustration see Fig. 3) may reveal function-
ally important, inter-modular residues, or residue-set, acting in con-
cert. Perturbation analysis [174,229] of ABC transporter protein 
structure networks may highlight protein segments which have a 
key role in the transmission of conformational changes. Game theo-
retical assessment [69,162,174] of the cooperation of ABC trans-
porter protein structure networks and their modules may highlight 
novel functional units. Inter-modular residues (or residue-sets) and 
modular centers of ABC transporter protein structure networks 
determining intra-protein information transmission, as well as their 
cooperative units may all be proven highly important in pharmacol-
ogical targeting of ABC transporters. The assessment of multi-
target drug action [129] or allo-network drugs [227] in the modifi-
cation of ABC transporter action may also give novel pharmacol-
ogical approaches in this important field. 
 We are at the very beginning of the understanding of ABC pro-
tein dynamics, as well as of the elucidation of their mechanism of 
action. However, from the studies summarized in our paper, it is 
already clear that the combination of computational and experimen-
tal tools to study the effect of physiologically important alterations 
in dynamics of ABC proteins will provide a very promising re-
search area in the coming years. 
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Fig. (3). Modules of ABC transporter protein structure network. The protein structure network of the ABC transporter Sav1866 (PDB ID: 2HYD) was assem-
bled using the HBPlus program [240] by converting the Cartesian coordinates of the 3D image to distances of amino acid pairs, and keeping all non-covalently 
bonded contacts within a distance of 0.4 nm and applying weights inversely representing the distance between amino acid residues. Modular analysis was 
performed by the Cytoscape plug-in of the ModuLand method [149]. On the figure modules of the Sav1866 protein structure network at the fourth hierarchical 
layer are shown (in each hierarchical layer modules of the layer below became meta-nodes of the upper layer and overlaps between modules of the layer below 
became edge-weights of the upper layer). Modules of the 4th hierarchical layer are projected back to the original protein structure network consisting of 
Sav1866 amino acids as nodes to allow a better comparison and are labeled with different colors. The network was visualized using the Pajek program [241]. 
Amino acids participating in the electrostatic interactions at the transmembrane domain and nucleotide binding domain interface [239] are highlighted with red 
contours and are labeled with arrows, while (small) diamonds label water molecules. Note that both the amino acids participating in the inter-domain electro-
static interactions and the connecting loops are situated at the overlap of major modules of the protein structure network. (The color version of the figure is 
available in the electronic copy of the article). 
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ABBREVIATIONS 
ABC = ATP binding cassette 
ADP = Adenosine diphosphate 
Arg = Arginine 
ATP = Adenosine triphosphate 
CFTR = Cystic fibrosis transmembrane conductance 
regulator 
EPR = Electron paramagnetic resonance 
ER = Endoplasmatic reticulum 
Gly = Glycine 
MDR = Multidrug resistance 
MDR1 = Multidrug-resistance protein 1 
MDR1A = Multidrug-resistance protein 1A 
MRP1 = Multidrug-resistance associated protein 1 
NBD = Nucleotide binding domain 
NMR = Nuclear magnetic resonance 
nsSNPs = Non-synonymous single nucleotide polymor-
phisms (SAPs) 
Phe = Phenylalanine 
Pi = Inorganic phosphate 
PKA = Protein kinase A 
PM = Plasmamembrane 
QSAR = Quantitative structure-activity relationship 
RI = Regulatory insertion 
RIN = Residue interaction network 
RND = Resistance-Nodulation-Division 
SAPs  = Non-synonymous single nucleotide polymor-
phisms (nsSNPs) 
Thr = Threonine 
TM = Transmembrane 
TMD = Transmembrane domain 
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